CCL2 and colorectal cancer: revealed that inhibiting the interaction between FAP+ fibroblasts and SPP1+ macrophages could improve immunotherapy for colorectal cancer.[31] Our research has yielded further evidence supporting the potential involvement of the CCL2‐CCR2 axis in BC recurrence and the feasibility of an anti‐tumor strategy targeting intercellular crosstalk.